相似文献
1
A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1.
J Virol. 1995 Jun;69(6):3752-8. doi: 10.1128/JVI.69.6.3752-3758.1995.
2
Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
Blood. 1995 Jul 15;86(2):659-65.
3
Analysis of viral gene expression and genome persistence in CD23-positive and -negative subpopulations of Epstein-Barr-virus-infected BL2 cells.
Intervirology. 1994;37(5):236-44. doi: 10.1159/000150384.
4
Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.
J Virol. 1990 May;64(5):2309-18. doi: 10.1128/JVI.64.5.2309-2318.1990.
5
Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells.
Br J Cancer. 1996 Aug;74(4):625-31. doi: 10.1038/bjc.1996.412.
6
The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines.
Int J Cancer. 1994 Apr 15;57(2):240-4. doi: 10.1002/ijc.2910570218.
7
Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP.
J Virol. 1988 Oct;62(10):3747-55. doi: 10.1128/JVI.62.10.3747-3755.1988.
8
Exclusive expression of Epstein-Barr virus nuclear antigen 1 in Burkitt lymphoma arises from a third promoter, distinct from the promoters used in latently infected lymphocytes.
Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6550-4. doi: 10.1073/pnas.88.15.6550.
9
Efficient EBV superinfection of group I Burkitt's lymphoma cells distinguishes requirements for expression of the Cp viral promoter and can activate the EBV productive cycle.
Virology. 1995 Feb 1;206(2):866-77. doi: 10.1006/viro.1995.1009.
10
Expression of Epstein-Barr virus BamHI-A rightward transcripts in latently infected B cells from peripheral blood.
Blood. 1999 May 1;93(9):3026-32.
引用本文的文献
1
Exploring the nuclear proteins, viral capsid protein, and early antigen protein using immunoinformatic and molecular modeling approaches to design a vaccine candidate against Epstein Barr virus.
Sci Rep. 2024 Jul 22;14(1):16798. doi: 10.1038/s41598-024-66828-x.
2
Treatment Options for Epstein-Barr Virus-Related Disorders of the Central Nervous System.
Infect Drug Resist. 2023 Jul 13;16:4599-4620. doi: 10.2147/IDR.S375624. eCollection 2023.
3
The Role of NK Cells in EBV Infection and EBV-Associated NPC.
Viruses. 2021 Feb 15;13(2):300. doi: 10.3390/v13020300.
4
Antibodies from Multiple Sclerosis Brain Identified Epstein-Barr Virus Nuclear Antigen 1 & 2 Epitopes which Are Recognized by Oligoclonal Bands.
J Neuroimmune Pharmacol. 2021 Sep;16(3):567-580. doi: 10.1007/s11481-020-09948-1. Epub 2020 Aug 18.
5
High Levels of IL-10 and CD4+CD25hi+ Treg Cells in Endemic Burkitt's Lymphoma Patients.
Biomedicines. 2015 Aug 4;3(3):224-236. doi: 10.3390/biomedicines3030224.
6
EBV Persistence--Introducing the Virus.
Curr Top Microbiol Immunol. 2015;390(Pt 1):151-209. doi: 10.1007/978-3-319-22822-8_8.
7
Isotypes of Epstein-Barr virus antibodies in rheumatoid arthritis: association with rheumatoid factors and citrulline-dependent antibodies.
Biomed Res Int. 2015;2015:472174. doi: 10.1155/2015/472174. Epub 2015 Apr 27.
8
Susceptibility of human placenta derived mesenchymal stromal/stem cells to human herpesviruses infection.
PLoS One. 2013 Aug 5;8(8):e71412. doi: 10.1371/journal.pone.0071412. Print 2013.
9
Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders.
Clin Dev Immunol. 2012;2012:931952. doi: 10.1155/2012/931952. Epub 2012 Jan 29.
10
Hematopoietic cells as sources for patient-specific iPSCs and disease modeling.
Cell Cycle. 2011 Sep 1;10(17):2840-4. doi: 10.4161/cc.10.17.17180.
本文引用的文献
1
Detection of multiple 'Ebnotypes' in individual Epstein-Barr virus carriers following lymphocyte transformation by virus derived from peripheral blood and oropharynx.
J Gen Virol. 1994 Jan;75 ( Pt 1):85-94. doi: 10.1099/0022-1317-75-1-85.
2
Clonality, expression and methylation patterns of the Epstein-Barr virus genomes in lethal midline granulomas classified as peripheral angiocentric T cell lymphomas.
J Gen Virol. 1994 Jan;75 ( Pt 1):77-84. doi: 10.1099/0022-1317-75-1-77.
3
Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state.
J Virol. 1994 Nov;68(11):7374-85. doi: 10.1128/JVI.68.11.7374-7385.1994.
4
Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4.
J Virol. 1993 Mar;67(3):1572-8. doi: 10.1128/JVI.67.3.1572-1578.1993.
5
One of two Epstein-Barr virus nuclear antigens contains a glycine-alanine copolymer domain.
Proc Natl Acad Sci U S A. 1983 Sep;80(18):5665-9. doi: 10.1073/pnas.80.18.5665.
6
A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection.
Proc Natl Acad Sci U S A. 1984 Nov;81(22):7207-11. doi: 10.1073/pnas.81.22.7207.
7
The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV.
Int J Cancer. 1971 Nov 15;8(3):443-50. doi: 10.1002/ijc.2910080312.
8
Antigen-driven selection of virgin and memory B cells.
Immunol Rev. 1986 Jun;91:61-85. doi: 10.1111/j.1600-065x.1986.tb01484.x.
9
Characterization of EBV-carrying B-cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth.
Int J Cancer. 1987 Apr 15;39(4):472-6. doi: 10.1002/ijc.2910390411.
10
Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders.
N Engl J Med. 1986 Apr 3;314(14):874-9. doi: 10.1056/NEJM198604033141403.
Zotero 插件